IMMUNOHISTOCHEMICAL ANALYSIS OF THE CYCLIN D1 BIOMARKER IN PAPILLIFEROUS THYROID CARCINOMAS AND MULTINODULAR GOITERS

• Autor(a) principal: Bartolomei, Ivan José Paredes
• Data de Publicação: 2022
• Outros Autores: Ribas, Carmen Austrália Paredes Marcondes, Zella, Maria Augusta Karas, Waaga-Gasser, Ana Maria, Gasser, Martin, Czeczko, Nicolau Gregori, Nassif, Paulo Afonso Nunes
• Tipo de documento: preprint
• Idioma: por
• Título da fonte: SciELO Preprints
• Texto Completo: https://preprints.scielo.org/index.php/scielo/preprint/view/4150
• topic: Carcinomas papilíferos de tireoide; Ciclina D1; Imunoistoquímica; Diagnóstico; Prognóstico; Papillary thyroid carcinomas; Cyclin D1; Immunohistochemistry

Background: Papillary thyroid carcinomas (PTC) are the most prevalent and least aggressive thyroid carcinomas. In some cases, the diagnosis is doubtfull and the prognosis is poor. The search for tissue biomarkers that make it possible to ensure both the diagnosis for indeterminate cases and the prognosis, identifying the most aggressive cases, has been studied in recent decades. Objective: To analyze the molecular marker cyclin D1 in PTC and multinodular goiter (BMN) and to verify the correlation of the marking with the clinical-pathological characteristics in carcinomas. Methods: 118 tissues from adult patients submitted to PTC thyroidectomy and 40 BMN were selected as a control group. Tissue immunostaining was performed with cyclin D1 with subsequent immunohistochemical analysis in both groups, evaluating the expression of the marker (intensity and distribution). In the PTC group, immunostaining data were also crossed with clinical and pathological data. Results: The majority (93.3%) expressed the staining of cyclin D1 with varying intensities (weak, moderate 3 and strong) and predominantly diffuse distribution (71.2%). The BMN control group expressed staining for cyclin D1 in 57.5%, with weak intensity (47.5%) and sparse distribution (37.5%). The difference between the groups (study and control) was statistically significant (p<0.001). In the CPT group, the clinical-pathological crossings did not show differences regarding age, sex, tumor type and size, lymph node status, focus, angiolymphatic invasion. Conclusion: Cyclin D1 was expressed in the vast majority of PTC with the predominant diffuse distribution. There was no correlation between the expression of cyclin D1 and any clinical-pathological characteristic of PTC.